New chemo cocktail tested for tough childhood cancers
NCT ID NCT00077285
Summary
This study is testing a specific combination of chemotherapy drugs (irinotecan and carboplatin) as the first treatment for children and young adults newly diagnosed with intermediate- or high-risk rhabdomyosarcoma, a type of muscle cancer. The goal is to see how well the tumor responds to this drug pair and to understand the side effects. For patients with the highest risk disease, the study also tests adding a longer-term 'maintenance' course of one of the drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.